Seawolf Therapeutics, a San Diego-based biotechnology company, announced its emergence from stealth with USD 100 million in financing to advance its proprietary DNA delivery platform, TRIDENT.
The company also unveiled a multi-target collaboration with Sanofi that carries milestones of up to USD 1.2 billion plus tiered royalties.
Financing Details
Founding investor Versant Ventures led Seawolf's seed round, followed by a Series A financing with participation from Versant, MPM BioImpact, and Novartis Venture Fund (NVF).
Additional investors include Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, and Pathway to Cures, the philanthropic venture arm of the National Bleeding Disorders Foundation, among others.
The capital will be used to advance the company's portfolio of therapeutics built on its redosable lipid nanoparticle (LNP)-based DNA delivery system. The company's lead proprietary program, aimed at metabolic diseases, is advancing to Development Candidate.
READ NEXT: Taiwan's OBI Pharma Partners with Novartis to Develop Next-Generation Antibody-Drug Conjugates
Sanofi Collaboration
Alongside the financing, Seawolf announced a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications.
The agreement includes up to USD 1.2 billion in research, development, and commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration.
"Seawolf is charting a new course in patient care through LNP-based DNA medicines," said Elizabeth Alcamo, Ph.D., president and CEO.
"With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs."
Trusted by Leading EPCs & Manufacturers
Find the Latest Pharmaceutical Plant Projects in the United States
Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information
Request Free Trial → Learn More →
No credit card Up-to-date coverage
The TRIDENT Platform
Seawolf's core technology, TRIDENT (Targeted RNA-Induced DNA Expression via Nuclear Translocation), is designed to match the potency, redosability, safety, and scalability of RNA-based LNP therapies while overcoming their short-lived expression by delivering DNA-based payloads.
The system consists of a proprietary LNP carrying an immune-quiet DNA that encodes a therapeutic transgene, along with an auxiliary factor that facilitates nuclear access.
According to the company, therapies built with TRIDENT are potent, durable, and have demonstrated a clean safety profile in primates. Unlike virus-based DNA platforms, the technology is redosable, allowing dosing to be fine-tuned or supplemented through repeat administration.
The company reports that the platform has generated sustained protein expression above therapeutic levels in primates at doses that are safe and well-tolerated.
The TRIDENT system can be deployed across a broad range of therapeutic areas, including replacing mutant genes and expressing biologics systemically. Seawolf has demonstrated proof-of-concept of the technology's applicability in both primates and murine preclinical models of metabolic and rare diseases.
Investor Perspective
"Nucleic acid-based therapies have advanced dramatically over the past decade," said Tom Woiwode, Ph.D., managing director at Versant and chair of Seawolf's board.
"The Seawolf team is now delivering on the promise of using DNA to drive robust and long-term expression of therapeutic proteins directly from the patient's own cells. I look forward to seeing this groundbreaking technology transform treatment options for patients."
About the Company
Seawolf Therapeutics is a privately held biotechnology company headquartered in San Diego, California, dedicated to transforming patient outcomes through its LNP-based DNA delivery platform.
The company's TRIDENT technology is designed to deliver DNA into the nucleus of cells to enable long-term, stable expression of therapeutic proteins in a non-immunogenic and redosable format.
Every Major Chemical Project in the United States, Mapped Before Your Competitors Hear About It
Consider the billions of dollars in chemical projects that launch across the United States each quarter, new chemical plants in Texas, expansions in Louisiana, and innovative recycling facilities in California. How many of these opportunities reach your desk while there's still time to act?
The Global Project Tracking (GPT) platform by Blackridge Research was specifically designed for the chemical sector. It aggregates and verifies project intelligence across all major chemical projects, enabling business development teams, suppliers, and investors to identify demand shifts months before official announcements.
From initial project conception to final completion, you receive a consistently updated overview of the entire chemical project lifecycle, rather than disjointed pieces found in press releases, permit databases, and industry publications.
Upcoming Projects
Tender Notices
Contract Awards
Projects Under Construction
Completed Projects
Book a Free Demo of the Global Project Tracking (GPT) platform by Blackridge Research and start tracking the US chemical pipeline today.
Leave a Comment
We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.
We read every comment and do our best to respond to them all.